CD274 and neoplasm: The multicentre, double-blind, randomized controlled trial conducted in 41 countries showed that the combination of atezolizumab, a PDL1 inhibitor, and nanoparticle albumin-bound (nab)-paclitaxel significantly improved progression-free survival (PFS) by 20% compared with nab-paclitaxel alone in the intention-to-treat population (median PFS 7.2 versus 5.5 months) and by 38% in the pre-defined subgroup of patients with PDL1 expression on ≥1% of tumour-infiltrating immune cells (median PFS 7.5 versus 5.0 months).